Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma

When pharmacologic costs of drugs are combined with the measure of efficacy represented by the OS, nivolumab is a cost-effective second-line treatment for patients with mRCC.